OneWorld Health begins final testing of drug to cure deadly kala azar in India
San Francisco, Calif. July 7, 2003 The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the United States, announced today it has begun Phase III testing of paromomycin to cure one of the world's deadliest parasitic diseases, kala azar, also known as visceral leishmaniasis (VL). Demonstrating a new use for an old medicine, OneWorld Health is developing paromomycin...OneWorld Health licenses compounds from Yale, U of Washington to treat major parasitic diseases
San Francisco, Calif. July 8, 2003 -- The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the United States, announced today it has licensed a novel class of high-potency compounds from Yale University and the University of Washington that could result in medicines for the developing and developed worlds.... ...The agreement gives OneWorld Health the exclusive licen...